OTC
Every company in the roster listed on OTC.
Every company in the roster listed on OTC.
16 of 16 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Bio-Path Holdings, Inc.BPTH · OTC | 2 assets: 1 Ph 2, 1 Ph 1 | PrexigebersenPhase 2 · Acute Myeloid LeukemiaWeak signal | Mar 2027BP1002 · Phase 1 | —no price since 18 Aug 2026 | <$0.1MMar 2026 | Ended Apr 2026 | $8.1M |
BioAtla, Inc.BCAB · OTC | 3 assets: 3 Ph 2 | Ozuriftamab vedotinPhase 2 · Head and Neck Squamous Cell CarcinomaPartial signal | None on record | —no price since 28 Aug 2026 | $1.5MJun 2026 | Ended Jul 2026 | $25M |
BioXcel Therapeutics, Inc.BTAI · OTC | 1 asset: 1 Ph 3 | Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal | 31 Jul 2027Dexmedetomidine (Igalmi) · Phase 1 | —no price since 4 Sep 2026 | $14MJun 2026 | Ended Oct 2026 | $22M |
CASI Pharmaceuticals, Inc.CASIF · OTC | 2 assets: 1 approved, 1 Ph 2 | CID-103Phase 2 · Immune ThrombocytopeniaWeak signal | 30 Nov 2028CID-103 · Phase 2 | —no price since 18 Aug 2026 | $5.6MDec 2025 | Ended Apr 2026 | $6.3M |
CERo Therapeutics Holdings, Inc.CERO · OTC | 1 asset: 1 Ph 1 | CER-1236Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026CER-1236 · Phase 1 | —no price since 18 Aug 2026 | $0.7MSep 2026 | Ended Oct 2026 | $7.3M |
Merck KGaAMKKGY · OTC | 8 assets: 7 approved, 1 Ph 3 | precemtabart tocentecanPhase 3 · Metastatic Colorectal Cancer | Apr 2027Cetuximab · Phase 1/2 | —no price since 18 Aug 2026 | — | Profitable | — |
NKGen BiotechNKGN · OTC | 1 asset: 1 Ph 2 | TroculeucelPhase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028Troculeucel · Phase 1/2 | —no price since 18 Aug 2026 | <$0.1MMar 2025 | Ended Mar 2025 | $9.3M |
| 1 asset: 1 other | LinebackerSolid Tumors | None on record | —no price since 18 Aug 2026 | <$0.1MJun 2026 | Ended Jul 2026 | $0.1M | |
Provectus PharmaceuticalsPVCT · OTC | 2 assets: 1 Ph 3, 1 Ph 2 | rose bengal disodiumPhase 3 · Locally Advanced Cutaneous Melanoma | None on record | —no price since 18 Aug 2026 | — | ~1.9 qtrsJun 2026 | $1.0M |
PureTech HealthPTCHF · OTC | 2 assets: 2 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 | —no price since 18 Aug 2026 | $281MDec 2024 | ~8.4 qtrs | $69M |
RocheRHHBY · OTC | 68 assets: 23 approved, 20 Ph 3, 7 Ph 2, 4 Ph 1, 14 other | astegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | Nov 2026Venetoclax · Phase 2 | —no price since 18 Aug 2026 | — | — | $14.7B |
Sangamo TherapeuticsSGMOQ · OTC | 1 asset: 1 Ph 2 | TX200Phase 1/2 · Kidney Transplant Rejection Prophylaxis | None on record | —no price since 18 Aug 2026 | $28MMar 2026 | Ended Jul 2026 | $113M |
UCBUCBJY · OTC | 16 assets: 10 approved, 1 Ph 3, 3 Ph 2, 2 Ph 1 | Staccato AlprazolamPhase 3 · EpilepsyReliable signal | 21 Dec 2026bimekizumab · Phase 3 | —no price since 18 Aug 2026 | — | — | ~$1.9B |
Vaccinex, Inc.VCNX · OTC | 1 asset: 1 Ph 2 | PepinemabPhase 1/2 · Alzheimer's DiseaseWeak signal | 31 Dec 2028Pepinemab · Phase 1/2 | —no price since 18 Aug 2026 | $1.1MDec 2024 | Ended Jan 2025 | $13M |
VaxxinityVAXX · OTC | 2 assets: 1 Ph 2, 1 Ph 1 | UB-311Phase 2 · Early Alzheimer's Disease | None on record | —no price since 17 Aug 2026 | $31MDec 2023 | Ended Jul 2024 | $36M |
Windtree TherapeuticsWINT · OTC | 1 asset: 1 Ph 2 | rostafuroxinPhase 2 · Resistant Hypertension with Adducin/Ouabain Polymorphisms | None on record | —no price since 14 Aug 2026 | $0.2MSep 2025 | Ended Oct 2025 | $8.6M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.